November 02, 2018

Participants ages 18-50 needed for HVTN 124 Phase 1 clinical trial

HVTN 124 is a Phase 1 clinical trial to test the safety and immune response of 1 experimental vaccine and adjuvant (a substance to “alert” the immune system) in healthy, HIV-uninfected adults ages 18-50. The study is 14 months in length with 13 visits to our clinic for the duration of the study. Of those 13 visits, you will be vaccinated at 5 visits. Visits to our clinic range from 30-90 minutes and entail a brief physical exam, small blood draw, vaccinations, HIV counseling and testing, and completion of a diary. You are compensated for your time and travel at $75 for initial screening and for follow-up visits, and $100 for the vaccination visits.